Gottlieb Highlights Drawback To Increasing US FDA Salaries: Resource Disparity
Executive Summary
Commissioner tells agency stakeholders that there could be intra-agency moves to centers and offices that can offer higher pay.
You may also be interested in...
CDER Hiring Is Booming: Flexibility Of Remote Work During Pandemic Helps Drive Numbers, Cavazzoni Says
Employment totals have also been aided by a (surprisingly) low attrition rate during the pandemic and CDER’s full use the ‘Cures’ authorities; 20% of CDER’s workforce has been hired under Cures.
Cures Act Hiring Authority Expansion Could Help Recruitment Woes, US FDA's Sharpless Says
Acting commissioner says greater flexibility in hiring has 'a real potential to solve some of our problems,' although only about 40-50 people have been added to date; recruitment and retention were very much on the minds of the FDA’s leadership at the recent BIO annual meeting, where center directors spoke of the long-term damage caused by the five-week partial government shutdown.
Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions
Long-planned OND 'modernization' to better match workflow, allow more time with stakeholders includes proposed restructuring that would boost number of offices overseeing review operations (adding four for a total of nine) and drug review divisions (adding 11 for a total of 30).